PUBLISHER: Lucintel | PRODUCT CODE: 1386205
PUBLISHER: Lucintel | PRODUCT CODE: 1386205
The future of the global pertussis vaccine market looks promising with opportunities in the vaccination center, hospital, and clinic markets. The global pertussis vaccine market is expected to reach an estimated $9.1 billion by 2030 with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are growing awareness of the importance of pertussis vaccination, supportive government initiatives to promote pertussis vaccination, and continous development of new pertussis vaccines.
A more than 150-page report is developed to help in your business decisions.
The study includes a forecast for the global pertussis vaccine by type, end use, and region.
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pertussis vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pertussis vaccine companies profiled in this report include-
Lucintel forecasts that Dtap will remain the larger segment due to its significant use as combinated vaccine that protects against diphtheria, tetanus, and pertussis.
North America is expected to witness highest growth over the forecast period due to increasing number of geriatric population and rising pertussis death cases in the region.
Market Size Estimates: Pertussis vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Pertussis vaccine market size by type, end use, and region in terms of value ($B).
Regional Analysis: Pertussis vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the pertussis vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pertussis vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Answer: The global pertussis vaccine market is expected to reach an estimated $9.1 billion by 2030.
Answer: The global pertussis vaccine market is expected to grow with a CAGR of 5.6% from 2024 to 2030.
Answer: The major drivers for this market are growing awareness of the importance of pertussis vaccination, supportive government initiatives to promote pertussis vaccination, and continous development of new pertussis vaccines.
Answer: The future of the pertussis vaccine market looks promising with opportunities in the vaccination center, hospital, and clinic markets.
Answer: Some of the key pertussis vaccine companies are as follows:
Answer: Lucintel forecasts that Dtap will remain the larger segment due to its significant use as combinated vaccine that protects against diphtheria, tetanus, and pertussis.
Answer: North America is expected to witness highest growth over the forecast period due to increasing number of geriatric population and rising pertussis death cases in the region.
Answer: Yes, Lucintel provides 10% customization without any additional cost.